|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||82.44 - 83.70|
|52 Week Range||69.35 - 89.72|
|PE Ratio (TTM)||22.96|
|Earnings Date||Feb 20, 2018|
|Forward Dividend & Yield||1.84 (2.25%)|
|1y Target Est||90.16|
Medtronic Plc has agreed to pay $12 million to resolve claims that the company engaged in a deceptive marketing strategy to promote its Infuse bone graft product used in spinal surgery, the Massachusetts attorney general said on Wednesday. Massachusetts Attorney General Maura Healey said the settlement will resolve an investigation by her office and those in four other states related to Medtronic's promotion of Infuse, which is used to stimulate bone growth. In court papers, Healey alleged that Medtronic sought to expand the device's market by using deceptive company-sponsored scientific literature to make false and misleading claims about its safety and superiority.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Medtronic Plc Here are 5 ETFs with the largest exposure to MDT-US. Comparing the performance and risk of Medtronic Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
The U.S. Food and Drug Administration on Monday proposed creating a new fast track to market for certain medical devices and a potential reduction in the amount of safety data required for approval. Commissioner Scott Gottlieb announced the proposal in a blog posted on the FDA's website. If implemented, it could save device companies millions of dollars in product testing and shave years off development times.
Shares of Abbott Laboratories (ABT) and Medtronic (MDT) are higher on Tuesday, following a pair of upgrades from BMO Capital Markets and Argus Research. BMO Analyst Joanne Wuensch and her team boosted their rating on the stock to Outperform from Market Perform and named it as one of their top picks for the year ahead. Wuensch writes that the move comes after its Alere and St. Jude Medical acquisitions behind it, it faces easier comparisons, and there are several new product launches ahead in 2018, making it a "year of execution." More from the note: Like everything in MedTech, stocks trade on the product pipeline, access to cash and valuation. As we exit 2017, Abbott has secured U.S. approval for its FreeStyle Libre Consumer (September 27, 2017, with increasing reimbursement throughout the year), Proclaim DRG Neurostimulator (October 6, 2017), HeartMate 3 LVAD (August 28, 2017), and MRI-conditional labelling for its Ellipse ICD (September 22, 2017).
Medtronic PLC (NYSE: MDT ) is poised for better opportunities ahead after a long period of underperformance, Argus said in a Tuesday note. The firm noted that shares of Medtronic have underperformed the ...
Categories: Yahoo FinanceGet free summary analysis Medtronic Plc reports financial results for the quarter ended October 31, 2017. We analyze the earnings along side the following peers of Medtronic Plc – Boston Scientific Corporation, Edwards Lifesciences Corporation, Stryker Corporation, Johnson & Johnson, Abbott Laboratories, CONMED Corporation, C. R. Bard, Inc., Baxter International Inc., Zimmer Biomet Holdings, Inc. ... Read more (Read more...)
DUBLIN - December 8, 2017 - The board of directors of Medtronic plc (NYSE:MDT) today approved the fiscal year 2018 third quarter cash dividend of $0.46 per ordinary share, representing a 7 percent increase ...
There are never any guarantees that past performance will equal future performance, but we are now just five weeks into the seasonally favorable November-April time of the year.
On June 26, 2017, Medtronic reported its 52-week high of $89.70, while the company's 52-week low stood at $69.30 on January 3, 2017.
In fiscal 2Q18, Medtronic used a portion of its divestiture proceeds toward stock buybacks. The total share repurchases in the quarter came in at ~$568.0 million.
Runaway success for this pioneer of robot-assisted surgery has inspired a slew of competitors to enter the arena.
Medtronic provides solutions to hospitals, which translate the clinical value to economic value for these hospitals.
DUBLIN - December 1, 2017 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that it will participate in the Citi 2017 Global Healthcare Conference on Wednesday, December ...
Medtronic's TYRX-based infection reduction program is accelerating at a strong pace. The number of accounts under this contract tripled to around 900 hospitals in fiscal 2Q18.
In fiscal 2Q18, Medtronic's Restorative Therapies Group business registered year-over-year sales growth of ~2.0%, which came in below expectations due to the negative impact of Hurricane Maria.
Due to the disappointing fiscal 2Q18 results, Medtronic made a downward revision to its estimates for MITG sales growth in fiscal 2018 to 3.0%–3.5%.
Medtronic's CVG (Cardiac and Vascular Group) business reported growth of ~7.0% on a YoY (year-over-year) basis.
Medtronic (MDT) reported net adjusted profits of ~$1.5 billion for fiscal 2Q18, an ~7.0% year-over-year decline. This report included an ~3.0% negative impact resulting from Hurricane Maria.
BD (BDX) has always focused on providing innovative products and solutions to its customers. The company makes considerable R&D (research and development) investments. In fiscal 4Q17, BD invested approximately ...